Abstracts from 2014 through the most recent CROI can be viewed in this searchable database once they have been presented at the conference. Abstract Contents: The searchable database includes abstract text as submitted by the authors prior to CROI. Study data might be updated during the presentation at CROI. Please refer to the electronic poster or webcast for updates. Searching the Abstract Database: Enter the criteria below and click the “Search” button. After the search has been entered, the results will appear below the search form.

CROI conference materials (eg, the conference program, Abstract eBook, electronic posters, CROI logo, etc) are protected by copyright. Permission to replicate or reproduce these elements, in whole or in part, must be obtained from the CROI Conference Manager, the International Antiviral Society-USA (IAS-USA). Study data (including figures within abstracts or electronic posters) are the property of the study authors. Permission to use data and figures cannot be given by IAS–USA unless it is for regulatory reasons. For more information, please email CROIabstracts@iasusa.org.

Search Results

1277 Results

1015 – Long-Acting Cabotegravir/Rilpivirine in Pregnancy

Background Long-acting cabotegravir and rilpivirine (LA-CAB/RPV) is a novel injectable antiretroviral therapy approved for virologically suppressed individuals with HIV-1. Data on the safety, efficacy, and outcomes for individuals receiving LA-CAB/RPV during pregnancy are limited. We evaluated HIV viral suppression, perinatal, and neonatal outcomes in pregnant persons with HIV-1 receiving LA-CAB/RPV. This is the first case…

1186 – Transfusion Risk of HIV, HBV, and HCV in Low- and Middle-Income Countries Without Nucleic Acid Testing

Background Nucleic acid testing (NAT) is a highly sensitive detection method routinely used to screen donated blood for human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV) in high-income countries. Despite this technology being available for decades, few low- and middle-income countries (LMIC) in sub-Saharan Africa (SSA) have implemented NAT. We…

1034 – Pediatric ART Interruptions Transiently Raise HIV DNA Without Large Changes to Long-Term Reservoirs

Background To inform pediatric HIV persistence inclusive of scenarios where antiretroviral therapy (ART) usage may not be completely suppressive, we sought to elucidate reservoir dynamics with and without occasional HIV RNA viremia. Methods In Kenyan children living with HIV who initiated ART between 1-12 months of age (median 3 months), we measured HIV RNA and HIV DNA…

1188 – HIV Recent Infection Surveillance Adds 17 Minutes to HIV Testing Services per Patient With HIV

Background Cost and implementation complexity of using HIV-1 Asanté rapid recency assays (ARRA) in routine HIV Testing Services (HTS) are previously cited concerns in scaling and sustaining HIV-1 recent infection surveillance (HRIS) in settings where workload of health care workers (HCW) remains high. We measured the additional time spent on facility-based and laboratory-based HRIS by…

1066 – Kidney Dysfunction in Young People Living With HIV on Dolutegravir-Based Regimens in Kampala, Uganda

Background Young people living with HIV (YPLHIV) are at increased risk of developing kidney abnormalities due to antiretroviral therapy (ART), particularly tenofovir disoproxil fumarate (TDF). Dolutegravir (DTG) is associated with increased creatinine levels. We explored the association of dolutegravir ART regimens with kidney abnormalities among YPLHIV in Kampala, Uganda. Methods We performed a cross-sectional study…

1190 – Machine Learning Risk Stratification Compared With a Counselor-Guided Screening Tool

Background Kenya has one of the largest HIV epidemics globally, with women constituting 62% of the 1.4 million people (15+ years) living with HIV. In 2023, Kenya has achieved 97% in 1st 95 recording 17 681 new HIV infections. Identifying the last 3% of individuals is becoming increasingly difficult. There’s a need to adopt targeted testing approaches hence…

1068 – Characterisation of Cardiac Disease in Adolescents With HIV in the Antiretroviral Therapy Era

Background Young people with perinatal HIV (PHIV) have an increased risk of cardiac disease despite effective ART, particularly but not exclusively in those who have had delayed HIV diagnosis and antiretroviral therapy (ART) initiation. The aim of the study is to characterize the myocardial abnormalities in adolescents with PHIV who are established on ART using…

1072 – HIV Modifies Association of Biomarkers on Cardiac Fibrosis and Inflammation in South African Youth

Background Few data exist on inflammatory markers and their association with myocardial fibrosis and inflammation in youth with HIV (YHIV). Methods The Cape Town Adolescent and Antiretroviral Cohort (CTAAC)-Heart study enrolled youth with perinatally acquired HIV (YPHIV), with non-perinatally acquired HIV (YNPHIV) and HIV-seronegative youth (HIV-) and performed cardiovascular magnetic resonance (CMR) to assess cardiac…

1080 – Identifying Effective Recruitment Strategies to Engage Black Sexual Minority Men Living With HIV

Background Identifying effective strategies to engage Black sexual minority men living with HIV (SMM LWH), including those with diversity in HIV care outcomes, socio-economic status, and geography, is crucial to obtaining a robust understanding of the HIV epidemiology in this population and developing effective public health programming to end the U.S. HIV epidemic. However, strategies…

1092 – Mpox Reinfections in California, May 2022 to August 2024

Background At the onset of the 2022 global mpox outbreak, infection from monkeypox virus was believed to offer long-term immunity. However, the first mpox reinfection in California was reported to the California Department Public of Health in April 2023. We sought to identify the frequency of mpox reinfections and associated characteristics to develop clinical and…